NCT01071512 - Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Multiple Sclerosis

Interventions

DRUG

Tysabri

Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.

Trial Locations (1)

60637

University of Chicago, Chicago